MaxCyte (MXCT:LSE) Annual Reports & Investor Relations Material

Overview

Rockville-based MaxCyte, Inc. is a leading global life sciences company specializing in discovering, developing, and commercializing next-generation cell therapies. MaxCyte's extensive product line includes the ExPERT ATx, a static electroporation instrument designed for small to medium scale transfection, and the ExPERT STx, a flow electroporation tool that is utilized for protein production and drug development. Additionally, MaxCyte offers the ExPERT GTx, which is a valuable flow electroporation tool suitable for large scale therapeutic applications, as well as the ExPERT VLx, tailored for very large volume cell-engineering. Further, MaxCyte also provides disposable processing assemblies (PAs) that are used to process and electroporate cells, along with accessories like electroporation buffer solution and software protocols. The company, founded in 1998, has since become synonymous with innovative and complex cell engineering techniques. MaxCyte's recent advancements in these technologies have enabled it to generate highly personalized, scalable therapies for various diseases. In short, by emboldening the discovery and commercialization of novel cell-based therapeutic solutions, MaxCyte will continue to contribute to some of the most innovative scientific breakthroughs in modern medicine.

Frequently Asked Questions

What is MaxCyte's ticker?

MaxCyte's ticker is MXCT

What exchange is MaxCyte traded on?

The company's shares trade on the LSE stock exchange

Where are MaxCyte's headquarters?

They are based in Gaithersburg, Maryland

How many employees does MaxCyte have?

There are 51-200 employees working at MaxCyte

What is MaxCyte's website?

It is maxcyte.com

What type of sector is MaxCyte?

MaxCyte is in the Healthcare sector